Melanoma 101 …But melanoma can also occur in the nail bed (acral lentiginous melanoma), in the eyes (ocular melanoma) and on internal…
Genetic Testing …need to contact their clinicians for sample collection. DecisionDx-Melanoma – This test evaluates 31 genes in the cutaneous (skin) melanoma…
Melanoma FAQs …risk factors for melanoma are. Are there Different Types of Melanoma? Yes, there are many different types and subtypes. Read…
Facts & Statistics …Prevalence, and Incidence Anyone, regardless of skin tone, can develop melanoma, but not all Americans are at equal risk of…
Understanding Melanoma …and on internal mucosal surfaces (mucosal melanoma), such as the lining of the sinuses, mouth, anal canal, or vagina. Melanoma can…
Ocular Melanoma Risk Factors …subtypes ocular melanoma (possibly uveal melanoma of the iris and conjunctival melanoma), but the majority of ocular melanomas are not…
Images of Melanoma in People with Skin of Color …Acral Lentiginous Melanoma.2015. Intech. doi: 10.5772/59133 Subungual melanoma on the fingernail Source: DermNet New Zealand Subungual melanoma on the left…
Ocular Melanoma What is Ocular Melanoma? Ocular melanoma is a rare form of melanoma that occurs in the eye. Though it develops from melanocytes, the same cell that…
How Ocular Melanoma is Diagnosed …recommended to check to see if the melanoma has spread to other parts of the body. Conjunctival melanomas are managed…
Understanding Your Pathology Report …in which case it would be described using the terms above, or a metastatic melanoma deposit. A metastatic melanoma deposit is one…
Jun. 09, 2026 The FDA Just Approved a New Sunscreen Ingredient— What It Means for Patients with Skin Cancer, Survivors, and the General Public
Jun. 05, 2026 Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective
Jun. 05, 2026 Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes
Jun. 05, 2026 Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors